Clinical Trials Directory

A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : AZD4877

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra). - Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy - Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting. - Ambulatory and capable of all selfcare more than 50% of waking hours

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
Not Recruiting

Footer Links: